Radius Health, Inc. (NASDAQ:RDUS) - Jefferies Group issued their Q3 2017 earnings per share estimates for Radius Health in a report released on Monday. Jefferies Group analyst E. Yang forecasts that the biopharmaceutical company will post earnings of ($1.31) per share for the quarter. Jefferies Group currently has a “Hold” rating and a $34.00 target price on the stock. Jefferies Group also issued estimates for Radius Health’s Q4 2017 earnings at ($1.20) EPS, FY2017 earnings at ($5.20) EPS, FY2019 earnings at ($3.57) EPS, FY2020 earnings at ($2.15) EPS and FY2021 earnings at $1.03 EPS.
Radius Health (NASDAQ:RDUS) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.18) by $0.14. During the same quarter in the prior year, the firm earned ($0.94) earnings per share.
ILLEGAL ACTIVITY WARNING: “Jefferies Group Weighs in on Radius Health, Inc.’s Q3 2017 Earnings (RDUS)” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://stocknewstimes.com/2017/08/07/jefferies-group-weighs-in-on-radius-health-inc-s-q3-2017-earnings-rdus-updated.html.
Other analysts have also recently issued reports about the company. Canaccord Genuity set a $85.00 price target on Radius Health and gave the stock a “buy” rating in a research report on Monday, July 17th. ValuEngine raised Radius Health from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Cowen and Company cut Radius Health from an “outperform” rating to a “market perform” rating in a research report on Tuesday, May 2nd. Cantor Fitzgerald set a $58.00 price objective on shares of Radius Health and gave the stock a “buy” rating in a report on Sunday, July 23rd. Finally, BidaskClub lowered shares of Radius Health from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $55.67.
Shares of Radius Health (NASDAQ:RDUS) opened at 41.07 on Wednesday. The stock’s market capitalization is $1.78 billion. The company’s 50 day moving average price is $43.82 and its 200-day moving average price is $40.67. Radius Health has a 12 month low of $31.58 and a 12 month high of $59.88.
In other news, major shareholder Growth N. V. Biotech acquired 43,400 shares of the firm’s stock in a transaction that occurred on Monday, May 8th. The stock was bought at an average cost of $35.57 per share, for a total transaction of $1,543,738.00. Following the acquisition, the insider now directly owns 4,785,999 shares in the company, valued at $170,237,984.43. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Growth N. V. Biotech acquired 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 2nd. The stock was purchased at an average price of $33.91 per share, with a total value of $2,543,250.00. Following the completion of the acquisition, the insider now owns 4,765,399 shares in the company, valued at $161,594,680.09. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 498,400 shares of company stock valued at $17,411,288. 15.00% of the stock is owned by company insiders.
A number of institutional investors have recently made changes to their positions in the company. C WorldWide Group Holding A S raised its position in shares of Radius Health by 0.6% in the first quarter. C WorldWide Group Holding A S now owns 7,397 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 43 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock worth $163,000 after buying an additional 46 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Radius Health by 3.1% in the first quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 180 shares during the last quarter. OppenheimerFunds Inc. raised its position in shares of Radius Health by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 301,631 shares of the biopharmaceutical company’s stock worth $11,658,000 after buying an additional 831 shares during the last quarter. Finally, Swiss National Bank raised its position in shares of Radius Health by 2.1% in the first quarter. Swiss National Bank now owns 49,700 shares of the biopharmaceutical company’s stock worth $1,921,000 after buying an additional 1,000 shares during the last quarter.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
